Skip to main content
MedPathMedPath Home
Clinical Trials/NCT04327479
NCT04327479
Completed
Not Applicable

Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection

University Hospital, Essen1 site in 1 country728 target enrollmentMarch 26, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCardiovascular DiseasesCardiovascular Risk FactorSARS

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiovascular Diseases
Sponsor
University Hospital, Essen
Enrollment
728
Locations
1
Primary Endpoint
All-cause mortality
Status
Completed
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects host-cells via ACE2-receptors, which leads to pneumonia (COVID-19) but also can lead to myocarditis (acute myocardial injury) and chronic damage to the cardiovascular system. Therefore, cardiovascular protection may be necessary when treating patients with COVID-19 infection. This may especially be necessary in patients with cardiovascular diseases, risk factors, and co-medication.

Registry
clinicaltrials.gov
Start Date
March 26, 2020
End Date
July 25, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital, Essen
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Patients with suspected SARS-CoV2/Covid-19 infection

Exclusion Criteria

  • •Unwillingness to participate

Outcomes

Primary Outcomes

All-cause mortality

Time Frame: During 1 year follow-up

mortality of any cause

Secondary Outcomes

  • Major adverse cardiovascular events(During 1 year follow-up)
  • 30-day mortality(Within 30 days after inclusion)

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Not Applicable
Endothelial Dysfunction in Covid-19Covid19Hypoxemic Respiratory Failure
NCT04830683Cliniques universitaires Saint-Luc- Université Catholique de Louvain85
Unknown
Not Applicable
Cardiovascular Manifestations of COVID-19Cardiovascular DiseasesCOVID
NCT04335630Memorial Hermann Health System500
Terminated
Phase 3
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?Covid19SARS-CoV Infection
NCT04606563University of British Columbia341
Completed
Not Applicable
Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUsSars-CoV2Covid-19
NCT04373759Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer186
Unknown
Not Applicable
Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19Covid19Myocardial InjuryCardiovascular DiseasesHeart FailureCardiovascular Morbidity
NCT04624503Humanitas Hospital, Italy500